AVO — Advanced Oncotherapy Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.61% | ||
| Return on Equity | -67.34% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | 33.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Advanced Oncotherapy Plc is a United Kingdom-based specialist developer and provider of a proton therapy system, the LIGHT system. The Company’s team, ADAM, based in Geneva, is focused on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control. The linear design of LIGHT allows for active longitudinal modulation along the proton beam axis and the variation of the proton beam by electronic means during cancer treatment. The modular feature of LIGHT offers hospitals and treatment centers the flexibility to customize cancer treatment plans based on a range of energies. Its subsidiaries include ADAM S.A., Advanced Oncotherapy Americas Inc, Advanced Oncotherapy B.V., Advanced Oncotherapy Resources Ltd, APTS Harley Street Ltd, Advanced Oncotherapy (China) Ltd, Advanced Oncotherapy Proton Therapy Services Ltd and other.
Directors
- Michael Sinclair CHM (78)
- Nicolas Serandour CEO
- Ed Lee COO
- Berengere Pons - Chabord SVF
- Louise Harley-Smeur SVP
- Graham Pughe SVP
- Steve Myers EDR
- Bridget Biggar DHR
- Michel Baelen OTH
- Jonathan Farr OTH
- Manuel Galas OTH
- Moataz Karmalawy OTH
- Benoit Raskin OTH
- Julian Tokuta OTH
- Michael Bradfield NED (69)
- Nick Plowman NED
- Enrico Vanni NED (70)
- Hans von Celsing NED
- Ren Zhang NED (55)
- Lori Cross NED (61)
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- September 15th, 2005
- Public Since
- August 4th, 2006
- No. of Employees
- 174
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 542,573,869
- Address
- Third Fl, 4 Tenterden Street, LONDON, W1S 1TE
- Web
- https://www.avoplc.com/
- Phone
- +44 2036178728
- Auditors
- RPG Crouch Chapman LLP
Latest News for AVO
Upcoming Events for AVO
Full Year 2022 Advanced Oncotherapy PLC Earnings Release
Half Year 2023 Advanced Oncotherapy PLC Earnings Release
Similar to AVO
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aptamer
London Stock Exchange
Belluscura
London Stock Exchange
FAQ
As of Today at 19:00 UTC, shares in Advanced Oncotherapy are trading at 1.93p. This share price information is delayed by 15 minutes.
Shares in Advanced Oncotherapy last closed at 1.93p and the price had moved by -91.44% over the past 365 days. In terms of relative price strength the Advanced Oncotherapy share price has underperformed the FTSE All Share Index by -91.59% over the past year.
The overall consensus recommendation for Advanced Oncotherapy is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
To buy shares in Advanced Oncotherapy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.93p, shares in Advanced Oncotherapy had a market capitalisation of .
Here are the trading details for Advanced Oncotherapy:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AVO
Based on an overall assessment of its quality, value and momentum Advanced Oncotherapy is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Oncotherapy. Over the past six months, its share price has underperformed the FTSE All Share Index by -86.53%.
As of the last closing price of 1.93p, shares in Advanced Oncotherapy were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Advanced Oncotherapy PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.93p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Advanced Oncotherapy's management team is headed by:
- Michael Sinclair - CHM
- Nicolas Serandour - CEO
- Ed Lee - COO
- Berengere Pons - Chabord - SVF
- Louise Harley-Smeur - SVP
- Graham Pughe - SVP
- Steve Myers - EDR
- Bridget Biggar - DHR
- Michel Baelen - OTH
- Jonathan Farr - OTH
- Manuel Galas - OTH
- Moataz Karmalawy - OTH
- Benoit Raskin - OTH
- Julian Tokuta - OTH
- Michael Bradfield - NED
- Nick Plowman - NED
- Enrico Vanni - NED
- Hans von Celsing - NED
- Ren Zhang - NED
- Lori Cross - NED